pericardial effusion |
Disease ID | 897 |
---|---|
Disease | pericardial effusion |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:9) C0007177 | cardiac tamponade | 56 C0018801 | heart failure | 11 C0031048 | constrictive pericarditis | 4 C0035078 | renal failure | 3 C0018800 | cardiomegaly | 3 C0264714 | acute heart failure | 3 C0012817 | diverticulum | 2 C0020542 | pulmonary hypertension | 2 C0020649 | hypotension | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:4) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs3764880 | 24445780 | 51311 | TLR8 | umls:C0031039 | BeFree | TLR7 rs3853839-G (G vs. C: p = 0.0100) and TLR8 rs3764880-G (recessive model: p = 0.0173; additive model: p = 0.0161) were associated with pericardial effusion in females relative to healthy females. | 0.000271442 | 2013 | TLR8;TLR8-AS1 | X | 12906707 | A | G |
rs3764880 | 24445780 | 51284 | TLR7 | umls:C0031039 | BeFree | TLR7 rs3853839-G (G vs. C: p = 0.0100) and TLR8 rs3764880-G (recessive model: p = 0.0173; additive model: p = 0.0161) were associated with pericardial effusion in females relative to healthy females. | 0.000271442 | 2013 | TLR8;TLR8-AS1 | X | 12906707 | A | G |
rs3853839 | 24445780 | 51284 | TLR7 | umls:C0031039 | BeFree | TLR7 rs3853839-G (G vs. C: p = 0.0100) and TLR8 rs3764880-G (recessive model: p = 0.0173; additive model: p = 0.0161) were associated with pericardial effusion in females relative to healthy females. | 0.000271442 | 2013 | TLR7 | X | 12889539 | C | G |
rs3853839 | 24445780 | 51311 | TLR8 | umls:C0031039 | BeFree | TLR7 rs3853839-G (G vs. C: p = 0.0100) and TLR8 rs3764880-G (recessive model: p = 0.0173; additive model: p = 0.0161) were associated with pericardial effusion in females relative to healthy females. | 0.000271442 | 2013 | TLR7 | X | 12889539 | C | G |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:16) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0031039 | arsenic trioxide | C006632 | 1327-53-3 | pericardial effusion | MESH:D010490 | marker/mechanism | 12669407 | ||
C0031039 | busulfan | D002066 | 55-98-1 | pericardial effusion | MESH:D010490 | marker/mechanism | 4691200 | ||
C0031039 | carbamazepine | D002220 | 298-46-4 | pericardial effusion | MESH:D010490 | marker/mechanism | 16283138 | ||
C0031039 | carmustine | D002330 | 154-93-8 | pericardial effusion | MESH:D010490 | marker/mechanism | 18344943 | ||
C0031039 | chlorthalidone | D002752 | 77-36-1 | pericardial effusion | MESH:D010490 | marker/mechanism | 3836295 | ||
C0031039 | clozapine | D003024 | 5786-21-0 | pericardial effusion | MESH:D010490 | marker/mechanism | 11870026 | ||
C0031039 | cyclophosphamide | D003520 | 50-18-0 | pericardial effusion | MESH:D010490 | marker/mechanism | 25023062 | ||
C0031039 | gemcitabine | C056507 | 103882-84-4 | pericardial effusion | MESH:D010490 | marker/mechanism | 16109609 | ||
C0031039 | indomethacin | D007213 | 53-86-1 | pericardial effusion | MESH:D010490 | marker/mechanism | 1923225 | ||
C0031039 | labetalol | D007741 | 36894-69-6 | pericardial effusion | MESH:D010490 | marker/mechanism | 9828745 | ||
C0031039 | methotrexate | D008727 | 1959/5/2 | pericardial effusion | MESH:D010490 | marker/mechanism | 10576662 | ||
C0031039 | methysergide | D008784 | 361-37-5 | pericardial effusion | MESH:D010490 | marker/mechanism | 15151680 | ||
C0031039 | minoxidil | D008914 | 38304-91-5 | pericardial effusion | MESH:D010490 | marker/mechanism | 12356348 | ||
C0031039 | thalidomide | D013792 | 50-35-1 | pericardial effusion | MESH:D010490 | marker/mechanism | 11972510 | ||
C0031039 | tretinoin | D014212 | 302-79-4 | pericardial effusion | MESH:D010490 | marker/mechanism | 1637024 | ||
C0031039 | valproic acid | D014635 | 99-66-1 | pericardial effusion | MESH:D010490 | marker/mechanism | 15901671 |
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D010490 | busulfex | busulfan | 6MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
FDA labeling changes(Total Drugs:1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D010490 | 01/13/2003 | busulfex | busulfan | Part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases | The population pharmacokinetic estimates of busulfan for clearance and volume of distribution were determined in an open-label, uncontrolled PK study in 24 pediatric patients 5 months to 16 years who received busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases Suggested dosing regimen | Labeling | B | - | - | - | Orphan Medical | 12/3/2002 | FALSE' |